Navigation Links
ImmunoVaccine Technologies Inc. Nears Phase I Clinical Trials with Completion of Scientific Advisory Board
Date:9/27/2007

HALIFAX, Sept. 27 /PRNewswire/ - ImmunoVaccine Technologies Inc. (IVT) finalizes an important step in its progress with the last appointment to its scientific advisory board (SAB), international oncology expert, Dr. Neil Berinstein.

Dr. Berinstein is the Global Head of the Cancer Vaccine Program at sanofi pasteur, and a professor at the University of Toronto's Department of Medicine. He has a long track record in fundamental research and has a significant publication record in the area of normal and malignant B cell biology, including articles, abstracts and book chapters on immunotherapeutic approaches for cancer including cancer vaccines. He was recently appointed vice-president of the Sabin Institute Cancer vaccine consortium. Dr. Berinstein received an MD from the University of Manitoba, and completed training programs at the University of Toronto in Internal Medicine and Medical Oncology. Following this, he spent four years as a post-doctoral fellow in Dr. Ron Levy's Lab at Stanford University working in the area of immunotherapy for cancer.

"IVT has very promising science," remarked Dr. Berinstein. "Their work is particularly interesting to me, and my commitment to new immunotherapeutic approaches for patients with cancer. "

ImmunoVaccine Technologies Inc. has been actively recruiting members to its SAB in preparation for its Phase I clinical trials, and sees this final appointment as a major stepping stone to that goal.

"This final appointment is one of the last steps before our Phase I clinical trials," said Dr. Martin Kast, chair of the scientific advisory board. "Dr. Berinstein's experience and insight are reflective of the quality of professionals that our exciting projects have attracted," continued Kast.

"Dr. Berinstein is a valuable addition to the team, and represents a pivotal point in our ongoing plan to introduce our patented vaccine platform," commented Dr. Randal Chase, president and CEO of IVT.

ImmunoVaccine Technologies Inc. (IVT) is a vaccine enhancement company focused on the commercialization of its patented VacciMax(R) platform. VacciMax(R) is a novel technology that can aid the development of new vaccines in human health applications with potential for both therapeutic cancer applications and preventative infectious disease vaccines. The opportunities for market applications and medical benefits are broad, and are currently being applied to cervical cancer, with potential for melanoma, breast, prostate and colon cancer treatments, as well as prevention therapies for influenza and other infectious diseases. http://www.immunovaccine.com


'/>"/>
SOURCE ImmunoVaccine Technologies Inc
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Barriers will not stop convergence of medical technologies
2. Merge Technologies net loss doubles to $10.1M
3. Making deals with evolving technologies in mind
4. Third Wave Technologies to raise $14.9M through private debt
5. Meier joins Broadlook Technologies as COO
6. Platypus Technologies secures $450K SBIR grant
7. Napier joins board of Third Wave Technologies
8. aOva Technologies raises $3 million
9. Consumer, business technologies face same challenges
10. Promega to get early access to WARF technologies under new agreement
11. Linda Weber to run Fiservs Interactive Technologies unit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Newly created 4Sight Medical ... to the healthcare market. The company's primary focus is on new product introductions, ... strategies that are necessary to help companies efficiently bring their products to market. ...
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
(Date:6/23/2016)... Prostate Cancer Foundation (PCF) is pleased to announce 24 new Young ... cancer. Members of the Class of 2016 were selected from a pool of ... More About the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology:
(Date:4/19/2016)... DUBAI , UAE, April 20, 2016 ... can be implemented as a compact web-based "all-in-one" system ... in the biometric fingerprint reader or the door interface ... requirements of modern access control systems. The minimal dimensions ... the ID readers into the building installations offer considerable ...
(Date:4/14/2016)... , April 14, 2016 ... and Malware Detection, today announced the appointment of ... the new role. Goldwerger,s leadership appointment comes ... the heels of the deployment of its platform at ... behavioral biometric technology, which discerns unique cognitive and physiological ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys has ... CEO, Barrett Bready , M.D., who returned to ... the original technical leadership team, including Chief Technology Officer, ... Product Development, Steve Nurnberg and Vice President of Software ... the company. Dr. Bready served as CEO ...
Breaking Biology News(10 mins):